OBJECTIVE -Glucagon-like peptide (GLP)-1 is a gut hormone that exerts incretin effects and suppresses food intake in humans, but its therapeutic use is limited due to its short half-life. This was a randomized, double-blind, parallel-group, placebo-controlled trial investigating the effect of the long-acting GLP-1 derivative liraglutide (NN2211) on glycemic control, body weight, body composition, and 24-h energy expenditure in obese subjects with type 2 diabetes.RESEARCH DESIGN AND METHODS -Thirty-three patients (mean Ϯ SD) aged 60.0 Ϯ 9.5 years, with HbA 1c 7.5 Ϯ 1.2% and BMI 36.6 Ϯ 4.1 kg/m 2 , were randomized to treatment with a single daily subcutaneous dose of 0.6 mg liraglutide (n ϭ 21) or placebo (n ϭ 12) for 8 weeks. In addition to weight and glycemic parameters, body composition was assessed by dual-energy X-ray absorptiometry (DEXA) scanning and 24-h energy expenditure in a respiratory chamber.RESULTS -After 8 weeks, liraglutide reduced fasting serum glucose (liraglutide, Ϫ1.90 mmol/l, and placebo, 0.27 mmol/l; P ϭ 0.002) and HbA 1c (liraglutide, Ϫ0.33%, and placebo, 0.47%; P ϭ 0.028) compared with placebo. No change in body weight was detected (liraglutide, Ϫ0.7 kg, and placebo, Ϫ0.9 kg; P ϭ 0.756). There was a nonsignificant trend toward a decrease in total fat mass (liraglutide, Ϫ0.98%, and placebo, Ϫ0.12%; P ϭ 0.088) and toward an increase in lean body mass (liraglutide, 1.02%, and placebo, 0.23%; P ϭ 0.118) in the liraglutide group compared with the placebo group. Twenty-four-hour energy expenditure was unaffected by the treatment (liraglutide, Ϫ12.6 kJ/h, and placebo, Ϫ13.7 kJ/h; P ϭ 0.799).CONCLUSIONS -Eight weeks of 0.6-mg liraglutide treatment significantly improved glycemic control without increasing weight in subjects with type 2 diabetes compared with those on placebo. No influence on 24-h energy expenditure was detected. Diabetes Care 27:1915-1921, 2004G lucagon-like peptide (GLP)-1 has several effects that make it a potential candidate molecule for the treatment of type 2 diabetes. GLP-1 is a peptide hormone secreted from the L-cells in the lower gut, i.e., the distal jejunum, ileum, and colon/rectum, in response to ingestion of carbohydrates, lipids, and mixed meals (1-3). GLP-1 stimulates postprandial insulin secretion and acts as an incretin hormone, thus potentiating glucose-stimulated insulin release. The incretin effect refers to the increased insulin response elicited by oral glucose compared with the response resulting from an isoglycemic intravenous infusion (4). In addition, GLP-1 has a suppressive effect on glucagon release and hepatic glucose output (5).Treatment of hyperglycemia in type 2 diabetic patients with GLP-1 has received much attention, but additional therapeutic indications could be envisioned. Within the last few years, the ability of GLP-1 to decrease appetite and energy intake has been established (6). A reduced food intake would support weight reduction attempts in patients with type 2 diabetes. The appetite-reducing effect might partly be related to the ability...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.